Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250

Journal of Nuclear Medicine

Volumn 52, Issue 4, 2011, Pages 535-540

  Pryma, Daniel A ^a   O'Donoghue, Joseph A ^b   Humm, John L ^b   Jungbluth, Achim A ^b   Old, Lloyd J ^b   Larson, Steven M ^b   Divgi, Chaitanya R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

124I cG250; Autoradiography; ImmunoPE.T.; Renal cancer

Indexed keywords

CARBONATE DEHYDRATASE IX; CG250; GIRENTUXIMAB I 124; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; AUTORADIOGRAPHY; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY TUMOR; MOLECULAR IMAGING; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RADIOACTIVITY; TUMOR BIOPSY; VENOUS BLOOD;

ADENOCARCINOMA, CLEAR CELL; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; AUTORADIOGRAPHY; CARBONIC ANHYDRASES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE FIXATION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79954591401     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083295     Document Type: Article

References (12)

1. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708-720.
2. Postel-Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in phase-I trials of novel molecularly targeted agents: Does dose matter? Br J Cancer. 2009;100: 1373-1378.
3. Eschmann SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760-767.
4. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med. 1992;33:2020-2023.
5. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729-2739. (Pubitemid 28523499)
6. Divgi CR, O'Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45:1412-1421. (Pubitemid 47618543)
7. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol.2007;8:304-310. (Pubitemid 46464522)
8. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol. 1993;11:738-750. (Pubitemid 23105683)
9. van Dijk J, Oosterwijk E, van Kroonenburgh MJ, et al. Perfusion of tumorbearing kidneys as a model for scintigraphic screening of monoclonal antibodies. J Nucl Med. 1988;29:1078-1082.
10. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529-1537. (Pubitemid 27167389)
11. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799. (Pubitemid 46630578)
12. 18F] fluoro-17b-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933-939.